This simulated analysis of cost-sharing in member nations of the Organisation for Economic Co-operation and Development found a large variation in costs borne by patients, often dependent on age, comorbidities, and socioeconomic status.
This population-based cohort study evaluates trends in the prescription and cost of generic atorvastatin among patients with commercial insurance coverage.
Using data from a single Canadian health center, this study examines the annual costs of prescribing laxatives in medical and surgical units.
This study estimates differences in the cost of injectable medication waste attributable to high vs low dead-space syringes.
This Viewpoint argues that the acceleration of the drug approval process could unequally distribute the costs and burdens of testing to vulnerable patient populations.
This cross-sectional study estimates potential savings through therapeutic substitution in terms of both overall and out-of-pocket expenditures of branded drugs when a generic in the same class with the same indication was available.
This study uses Medicare Part D prescriptions claims data and Massachusetts physicians payment database data to evaluate associations between industry payments to physicians and prescribing of brand-name statins.
This survey study investigates attitudes toward prescribing generic drugs among internists and specialists in endocrinology, hematology, and infectious diseases.
This evidence review examines whether the sacubitril-valsartan benefits seen in a trial persist over many years, its cost-effectiveness, and its budgetary impact on the health care system.
This decision-analytic model of treatment for hepatitis C virus genotype 1 assesses the cost-effectiveness of treating all patients with hepatitis C virus infection at all stages of fibrosis vs those with advanced fibrosis only in a US treatment-naive population sample.
This evidence summary reviews the comparative clinical effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitor for the treatment of adults with familial hypercholesterolemia or cardiovascular disease and who require additional lowering of low-density lipoprotein cholesterol levels.
This pharmacoepidemiology study assessed medication adherence before and after implementation of narrow insurance networks within commercial drug plans.
This study found that between 1991 and 2014, there was an upward trend in Medicaid payments for insulin products regardless of formulation, duration of action, and whether the product was patented, which suggests a lack of price competition for this class of medications.
This evidence report on interferon-free therapy for chronic hepatitis C virus infection includes a systematic review of the literature, a cost-effectiveness model, and a budget impact assessment to support a December 2014 public meeting of the California Technology Assessment Forum.